Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Eva Habjan"'
Autor:
Eva Habjan, Vien Q. T. Ho, James Gallant, Gunny van Stempvoort, Kin Ki Jim, Coen Kuijl, Daan P. Geerke, Wilbert Bitter, Alexander Speer
Publikováno v:
Disease Models & Mechanisms, Vol 14, Iss 12 (2021)
Finding new anti-tuberculosis compounds with convincing in vivo activity is an ongoing global challenge to fight the emergence of multidrug-resistant Mycobacterium tuberculosis isolates. In this study, we exploited the medium-throughput capabilities
Externí odkaz:
https://doaj.org/article/39606835a70f4e1685863ba3b6a406f5
Autor:
Vien Q. T. Ho, Mark K. Rong, Eva Habjan, Samantha D. Bommer, Thang V. Pham, Sander R. Piersma, Wilbert Bitter, Eelco Ruijter, Alexander Speer
Publikováno v:
Biomolecules, Vol 13, Iss 2, p 211 (2023)
The ESX-5 secretion system is essential for the viability and virulence of slow-growing pathogenic mycobacterial species. In this study, we identified a 1,2,4-oxadiazole derivative as a putative effector of the ESX-5 secretion system. We confirmed th
Externí odkaz:
https://doaj.org/article/ba497c40122b4f66a0f66f5d3ffc5e2c
Autor:
Gunny van Stempvoort, Alexander Speer, Coen Kuijl, Vien Q. T. Ho, Eva Habjan, Kin Ki Jim, James Gallant, Wilbert Bitter, Daan P. Geerke
Publikováno v:
Habjan, E, Ho, V Q T, Gallant, J, van Stempvoort, G, Jim, K K, Kuijl, C, Geerke, D P, Bitter, W & Speer, A 2021, ' An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor ', DMM Disease Models and Mechanisms, vol. 14, no. 12, dmm049145 . https://doi.org/10.1242/dmm.049145
Habjan, E, Ho, V Q T, Gallant, J, van Stempvoort, G, Jim, K K, Kuijl, C, Geerke, D P, Bitter, W & Speer, A 2021, ' An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor ', Disease Models and Mechanisms, vol. 14, no. 12 . https://doi.org/10.1242/dmm.049145
Disease Models and Mechanisms, 14(12). Company of Biologists Ltd
DMM Disease Models and Mechanisms, 14(12):dmm049145. Company of Biologists Ltd
Disease Models & Mechanisms, Vol 14, Iss 12 (2021)
Disease Models & Mechanisms
article-version (VoR) Version of Record
Habjan, E, Ho, V Q T, Gallant, J, van Stempvoort, G, Jim, K K, Kuijl, C, Geerke, D P, Bitter, W & Speer, A 2021, ' An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor ', Disease Models and Mechanisms, vol. 14, no. 12 . https://doi.org/10.1242/dmm.049145
Disease Models and Mechanisms, 14(12). Company of Biologists Ltd
DMM Disease Models and Mechanisms, 14(12):dmm049145. Company of Biologists Ltd
Disease Models & Mechanisms, Vol 14, Iss 12 (2021)
Disease Models & Mechanisms
article-version (VoR) Version of Record
Finding new anti-tuberculosis compounds with convincing in vivo activity is an ongoing global challenge to fight the emergence of multidrug-resistant Mycobacterium tuberculosis isolates. In this study, we exploited the medium-throughput capabilities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b997964d981d57640f57146042559c71
https://hdl.handle.net/1871.1/bbdc69b6-9121-4f07-bf2c-30353ecda6fd
https://hdl.handle.net/1871.1/bbdc69b6-9121-4f07-bf2c-30353ecda6fd
Publikováno v:
Antimicrobial Agents and Chemotherapy, 65(4):e01445-20. American Society for Microbiology
Ho, V Q T, Verboom, T, Rong, M K, Habjan, E, Bitter, W & Speer, A 2021, ' Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis ', Antimicrobial Agents and Chemotherapy, vol. 65, no. 4, e01445-20 . https://doi.org/10.1128/AAC.01445-20
Antimicrobial agents and chemotherapy, 65(4):e01445-20, 1-13. American Society for Microbiology
Ho, V Q T, Verboom, T, Rong, M K, Habjan, E, Bitter, W & Speer, A 2021, ' Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis ', Antimicrobial agents and chemotherapy, vol. 65, no. 4, e01445-20, pp. 1-13 . https://doi.org/10.1128/AAC.01445-20
Ho, V Q T, Verboom, T, Rong, M K, Habjan, E, Bitter, W & Speer, A 2021, ' Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis ', Antimicrobial Agents and Chemotherapy, vol. 65, no. 4, e01445-20 . https://doi.org/10.1128/AAC.01445-20
Antimicrobial agents and chemotherapy, 65(4):e01445-20, 1-13. American Society for Microbiology
Ho, V Q T, Verboom, T, Rong, M K, Habjan, E, Bitter, W & Speer, A 2021, ' Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis ', Antimicrobial agents and chemotherapy, vol. 65, no. 4, e01445-20, pp. 1-13 . https://doi.org/10.1128/AAC.01445-20
Screening strategies for antituberculosis compounds using Mycobacterium tuberculosis are time consuming and require biosafety level 3 (BSL3) facilities, which makes the development of high-throughput assays difficult and expensive. Mycobacterium mari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5256fcfa59f6cc0b15f977a654ef1c3
https://research.vumc.nl/en/publications/e42dacd6-5ceb-4a3d-9a47-1e712172ac1d
https://research.vumc.nl/en/publications/e42dacd6-5ceb-4a3d-9a47-1e712172ac1d
Publikováno v:
Antimicrob Agents Chemother
Screening strategies for antituberculosis compounds using Mycobacterium tuberculosis are time consuming and require biosafety level 3 (BSL3) facilities, which makes the development of high-throughput assays difficult and expensive. Mycobacterium mari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0cd95d0232cd2b67106c69f229ff4ae5
https://pubmed.ncbi.nlm.nih.gov/33495223
https://pubmed.ncbi.nlm.nih.gov/33495223